Left ventricular non-compaction associated with a genetic variant of the CYP2C9 gene.
Polymorphisms in the CYP2C9 gene can have a significant impact on drug therapy by affecting the pharmacokinetics of frequently prescribed drugs, such as phenprocoumon and warfarin. It is essential therefore that genetic CYP2C9 variants are excluded in patients with a suspected intolerance of anticoagulant therapy. Here we present the first report of a case of left ventricular non-compaction syndrome associated with a genetic variant of the CYP2C9 gene in a 45-year-old woman with myocardial insufficiency who was scheduled for implantation of a cardioverter defibrillator.
Bohrer
Thomas
T
Department of Cardiothoracic Surgery, Julius-Maximilians University of Wuerzburg, Oberduerrbacherstr. 7, 97080 Wuerzburg, Germany. Bohrer_T.htc@klinik.uni-wuerzburg.de
Klein
Hanns-Georg
HG
Elert
Olaf
O
D000483:Alleles; D000925:Anticoagulants / Q000009:adverse effects; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D009202:Cardiomyopathies / Q000209:etiology / Q000503:physiopathology*; D065729:Cytochrome P-450 CYP2C9; D004361:Drug Tolerance; D005260:Female; D014644:Genetic Variation; D006352:Heart Ventricles / Q000002:abnormalities / Q000503:physiopathology; D006801:Humans; D008875:Middle Aged; D013577:Syndrome; D018487:Ventricular Dysfunction, Left / Q000235:genetics* / Q000503:physiopathology*
D000925:Anticoagulants; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases